The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
CB&I
Advised McDermott International, Inc., a leading provider of integrated engineering, procurement, construction, installation and module fabrication services for upstream field developments worldwide, on its combination with CB&I, a leading provider of technology and infrastructure for the energy industry
36.5% stake in DNV GL Group AS
Advised Det Norske Veritas Holding AS (“DNV”) on its acquisition of the 36.5% stake in DNV GL Group AS it did not already own from Mayfair Vermögensverwaltungs SE, whereby DNV is becoming the sole shareholder and regaining full control of DNV GL
Grupo Sidecu
Advised the shareholders of Grupo Sidecu, the leading concessional sport center operator in Spain, on its sale of a controlling stake to Portobello Capital, a local private equity fund
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
Mãe Terra Produtos Naturais Ltda.
Advised Mãe Terra Produtos Naturais Ltda., Brazil’s leading Natural & Organic food products company, on its sale to The Unilever Group
B-G Mechanical Contractors, Inc., B-G Mechanical Services, Inc., Elmsford Sheet Metal Works, Inc., Fred Williams, Inc., H.T. Lyons, Inc. and TryState Mechanical, Inc.
Advised Talen Energy, one of the largest independent energy and power producers in the United States, on the sale of six subsidiaries, within its Mechanical Services business, to Engie North America
Morris Corporation
Advised Morris Corporation, a leading independent player in Australia’s remote facilities management sector, on its sale to Sodexo SA, a France-based leading global facilities services company
Thermamax
Advised the shareholders of Thermamax, a leading family-owned manufacturer of highly engineered high temperature insulation solutions on the sale of the Company
Deltaplam
Advised Deltaplam, a Brazilian flexible packaging manufacturer, on its 100% sale to Sealed Air Corporation, a global provider of knowledge-based food, product and medical packaging solutions
Radiogroup Participações S.A.
Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas
LCH.Clearnet SA
Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated
Subsidiaries and affiliates of Empresas Indumotora S.A.
Advised Inchcape PLC, a global leader in automotive retail and distribution, on the acquisition of a multi-country scale distribution business in Chile, Peru, Colombia, and Argentina for $290m (approximately £234m)
Rico
Advised the founding shareholders of Rico, a leading independent online investment platform in Brazil, on its 100% sale to XP Investimentos, a Brazilian investment firm
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Fragrance Resources Group
Advised IFF, one of the world’s largest flavors and fragrances businesses, on the acquisition of Fragrance Resources Group, a family-owned fragrance company headquartered in Switzerland
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
Valves & Controls Business of Pentair
Advised Emerson, a diversified global technology and industrial company, on the acquisition of the Valves & Controls business of Pentair
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories